Expertise in
9
conditions

Dr. Edgar Overton

Infectious Disease
Univ. Of Alabama At Birmingham
908 20th St S, 
Birmingham, AL 
27 Years of Experience
Expertise in
9
conditions
Univ. Of Alabama At Birmingham
908 20th St S, 
Birmingham, AL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Edgar Overton is an Infectious Disease provider in Birmingham, Alabama. Dr. Overton has been practicing medicine for over 27 years is highly rated in 9 conditions, according to our data. His top areas of expertise are HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex.

His clinical research consists of co-authoring 178 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Infectious Disease
Licenses
Internal Medicine in AL
Hospital Affiliations
University Of Alabama Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Univ. of Alabama at Birmingham
908 20th St S, Birmingham, AL 35205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Immunogenicity of Nonavalent HPV Vaccine Administered Prior to Renal Transplantation in Adults: A Prospective, Single-Arm, Multi-Center Clinical Trial
Immunogenicity of Nonavalent HPV Vaccine Administered Prior to Renal Transplantation in Adults: A Prospective, Single-Arm, Multi-Center Clinical Trial
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Biological, Other, Procedure
Study Drug: Recombinant Human Papillomavirus Nonavalent Vaccine
Study Phase: Phase 2
A Proof-of Concept, Randomized, Controlled Study of Tuberculosis Immunization With BCG to Prevent Infection in Healthy Adults (TIPI Trial)
A Proof-of Concept, Randomized, Controlled Study of Tuberculosis Immunization With BCG to Prevent Infection in Healthy Adults (TIPI Trial)
Enrollment Status: Terminated
Publish Date: January 23, 2026
Intervention Type: Drug, Biological
Study Phase: Phase 3
Nonalcoholic Fatty Liver Disease In Persons Living With HIV Database Study
Nonalcoholic Fatty Liver Disease In Persons Living With HIV Database Study
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: December 04, 2024
Intervention Type: Other, Biological
Study Drugs: Quadrivalent Inactivated Influenza Vaccine, Trivalent Influenza Vaccine
Study Phase: Phase 2
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
Enrollment Status: Completed
Publish Date: October 21, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Biological
Study Phase: Phase 3
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)
Enrollment Status: Completed
Publish Date: June 06, 2018
Intervention Type: Device, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

178 Total Publications

APOL1 Genotype and HIV Infection: 20-Year Outcomes for CKD, Cardiovascular Disease, and Hypertension.
APOL1 Genotype and HIV Infection: 20-Year Outcomes for CKD, Cardiovascular Disease, and Hypertension.
Journal: Kidney international reports
Published: October 22, 2024
Similar Doctors
Michael Saag
Expertise in
9
conditions
Dr. Michael Saag
Infectious Disease
Expertise in
9
conditions
Dr. Michael Saag
Infectious Disease

1917 Outpatient Clinic At UAB

3220 5th Ave S, 
Birmingham, AL 
 (1.3 miles away)
205-934-1917
Languages Spoken:
English
See accepted insurances

Michael Saag is an Infectious Disease provider in Birmingham, Alabama. Dr. Saag is highly rated in 9 conditions, according to our data. His top areas of expertise are HIV/AIDS, Hepatitis C, Hepatitis, and Myelitis.

Peter Pappas
Expertise in
7
conditions
Dr. Peter Pappas
Infectious Disease
Expertise in
7
conditions
Dr. Peter Pappas
Infectious Disease

University Of Alabama Hospital

619 19th St S, 
Birmingham, AL 
 (0.1 miles away)
205-934-6600
Languages Spoken:
English
See accepted insurances

Peter Pappas is an Infectious Disease provider in Birmingham, Alabama. Dr. Pappas is highly rated in 7 conditions, according to our data. His top areas of expertise are Cryptococcosis, Sepsis, Blastomycosis, Angioplasty, and Stent Placement.

David Kimberlin
Expertise in
13
conditions
Dr. David Kimberlin
Infectious Disease
Expertise in
13
conditions
Dr. David Kimberlin
Infectious Disease

Children's Of Alabama

1600 7th Ave S, 
Birmingham, AL 
 (0.3 miles away)
205-996-6097
Languages Spoken:
English
See accepted insurances

David Kimberlin is an Infectious Disease provider in Birmingham, Alabama. Dr. Kimberlin is highly rated in 13 conditions, according to our data. His top areas of expertise are Neonatal Herpes, Congenital Cytomegalovirus, Genital Herpes, and Cytomegalovirus Infection.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Overton's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile